Cameron D Thomas,
Postdoctoral Associate
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6446
Business Email:
camerondthomas@ufl.edu
Publications
2021
A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(4):621-628
[DOI] 10.1038/s41436-020-01050-4.
[PMID] 33420349.
2021
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Clinical pharmacology and therapeutics.
109(6):1417-1423
[DOI] 10.1002/cpt.2015.
[PMID] 32770672.
2021
How to Integrate CYP2D6 Phenoconversion into Clinical Pharmacogenetics: A Tutorial.
Clinical pharmacology and therapeutics.
[DOI] 10.1002/cpt.2354.
[PMID] 34231197.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
109(3):705-715
[DOI] 10.1002/cpt.2039.
[PMID] 32897581.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology.
9(12):678-685
[DOI] 10.1002/psp4.12563.
[PMID] 33067866.
2020
Pharmacogenetic factors affecting β-blocker metabolism and response.
Expert opinion on drug metabolism & toxicology.
16(10):953-964
[DOI] 10.1080/17425255.2020.1803279.
[PMID] 32726152.
2019
Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease.
Journal of clinical pharmacy and therapeutics.
44(1):109-114
[DOI] 10.1111/jcpt.12767.
[PMID] 30311242.
Contact Details
Phones:
- Business:
- (352) 273-6446
Emails:
- Business:
- camerondthomas@ufl.edu